In latest news on Replicel they seem to be structuring company to generate appeal for additional financing. Also mentions their success in clinical trials:
http://editorial.equities.com/spotlight-companies/replicel-converts-class-c-shares-to-common-stock/
http://editorial.equities.com/spotlight-companies/replicel-converts-class-c-shares-to-common-stock/